In July 2020, the US Food and Drug Administration (FDA) published the draft guidance entitled Cannabis and Cannabis Derived Compounds: Quality Considerations for Clinical Research Guidance for Industry. The 12-page draft contains non-binding recommendations and is not for implementation. Instead, Julie Odland at Clarivate shows why the FDA draft guidance is intended for public comment for the agency to consider as it compiles the final version of the guidance.